Connecting you to content on EBSCOhost

Works by Sundby Palle, Mads

Results: 3

1

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 710, doi. 10.1111/dom.16065

By:

Armstrong, Matthew J.;
Okanoue, Takeshi;
Sundby Palle, Mads;
Sejling, Anne‐Sophie;
Tawfik, Mohamed;
Roden, Michael

Publication type:

Article

2

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 6, p. 929, doi. 10.1111/dom.13978

By:

Blonde, Lawrence;
Belousova, Lidia;
Fainberg, Udi;
Garcia‐Hernandez, Pedro A.;
Jain, Sunil M.;
Kaltoft, Margit S.;
Mosenzon, Ofri;
Nafach, Jalal;
Palle, Mads Sundby;
Rea, Rosangela

Publication type:

Article

3

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging.

Published in:

Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 9, p. 1150, doi. 10.1111/apt.16608

By:

Flint, Anne;
Andersen, Grit;
Hockings, Paul;
Johansson, Lars;
Morsing, Anni;
Sundby Palle, Mads;
Vogl, Thomas;
Loomba, Rohit;
Plum‐Mörschel, Leona

Publication type:

Article